DNA
NYSE · Life Sciences Tools & Services
Ginkgo Bioworks Holdings Inc
$9.04
-0.13 (-1.42%)
Financial Highlights (FY 2026)
Revenue
205.59M
Net Income
-377,888,666
Gross Margin
72.4%
Profit Margin
-183.8%
Rev Growth
-29.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 72.4% | 72.4% | 41.7% | 41.7% |
| Operating Margin | -194.9% | -175.4% | 15.3% | 12.5% |
| Profit Margin | -183.8% | -174.6% | 11.7% | 14.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 205.59M | 290.01M | 190.96M | 198.93M |
| Gross Profit | 148.82M | 209.94M | 79.67M | 82.99M |
| Operating Income | -400,664,701 | -508,672,917 | 29.13M | 24.90M |
| Net Income | -377,888,666 | -479,757,087 | 22.33M | 29.70M |
| Gross Margin | 72.4% | 72.4% | 41.7% | 41.7% |
| Operating Margin | -194.9% | -175.4% | 15.3% | 12.5% |
| Profit Margin | -183.8% | -174.6% | 11.7% | 14.9% |
| Rev Growth | -29.1% | -29.1% | +20.3% | +23.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 38.12M | 33.29M |
| Total Equity | — | — | 235.49M | 239.75M |
| D/E Ratio | — | — | 0.16 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -329,403,775 | -441,435,443 | 37.06M | 33.75M |
| Free Cash Flow | — | — | 21.64M | 24.30M |